← All Axsome Therapeutics, INC filings

Axsome Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
AXSM
Axsome Therapeutics, INC
DEF: Axsome Therapeutics 2026 Annual Meeting Proxy Statement
Axsome Therapeutics has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory vote.
NASDAQ
AXSM
Axsome Therapeutics, INC
DEFA14A: Axsome Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals
Axsome Therapeutics has scheduled its 2025 Annual Meeting for June 6, 2025, and is seeking stockholder votes on director election, incentive plan approval, auditor ratification, and executive compensation.
NASDAQ
AXSM
Axsome Therapeutics, INC
DEF: Axsome Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Axsome Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 6, 2025, featuring proposals including director election, incentive plan approval, auditor ratification, and executive compensation advisory vote.
NASDAQ
AXSM
Axsome Therapeutics, INC
DEF 14A: Axsome Therapeutics Sets Date for 2024 Annual Stockholders Meeting
Axsome Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.